145 related articles for article (PubMed ID: 36580345)
1. Two to tango! IL-13 and TGF-β drive myelofibrosis.
Jutzi JS; Mullally A
Blood; 2022 Dec; 140(26):2767-2768. PubMed ID: 36580345
[No Abstract] [Full Text] [Related]
2. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow.
Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675
[TBL] [Abstract][Full Text] [Related]
4. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
6. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.
Chagraoui H; Komura E; Tulliez M; Giraudier S; Vainchenker W; Wendling F
Blood; 2002 Nov; 100(10):3495-503. PubMed ID: 12393681
[TBL] [Abstract][Full Text] [Related]
7. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC
Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
[TBL] [Abstract][Full Text] [Related]
8. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms.
Melo-Cardenas J; Bezavada L; Crawford JC; Gurbuxani S; Cotton A; Kang G; Gossett J; Marinaccio C; Weinberg R; Hoffman R; Migliaccio AR; Zheng Y; Derecka M; Rinaldi CR; Crispino JD
Blood; 2022 Dec; 140(26):2805-2817. PubMed ID: 36283106
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC;
Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
[TBL] [Abstract][Full Text] [Related]
10. Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-beta1.
Okabe S; Miyazawa K; Iguchi T; Sumi M; Takaku T; Ito Y; Kimura Y; Serizawa H; Mukai K; Ohyashiki K
Leuk Lymphoma; 2005 Apr; 46(4):599-602. PubMed ID: 16019489
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1
Arciprete F; Verachi P; Martelli F; Valeri M; Balliu M; Guglielmelli P; Vannucchi AM; Migliaccio AR; Zingariello M
Exp Hematol; 2023 May; 121():30-37. PubMed ID: 36863479
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis.
Teodorescu P; Pasca S; Jurj A; Gafencu G; Joelsson JP; Selicean S; Moldovan C; Munteanu R; Onaciu A; Tigu AB; Buse M; Zimta AA; Stiufiuc R; Petrushev B; Desmirean M; Dima D; Vlad C; Bergthorsson JT; Berce C; Ciurea S; Ghiaur G; Tomuleasa C
J Cell Mol Med; 2020 Oct; 24(19):11100-11110. PubMed ID: 32889753
[TBL] [Abstract][Full Text] [Related]
13. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-4- and interleukin-13-enhanced transforming growth factor-beta2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma.
Wen FQ; Kohyama T; Liu X; Zhu YK; Wang H; Kim HJ; Kobayashi T; Abe S; Spurzem JR; Rennard SI
Am J Respir Cell Mol Biol; 2002 Apr; 26(4):484-90. PubMed ID: 11919085
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis.
Martyré MC; Romquin N; Le Bousse-Kerdiles MC; Chevillard S; Benyahia B; Dupriez B; Demory JL; Bauters F
Br J Haematol; 1994 Sep; 88(1):9-16. PubMed ID: 7803262
[TBL] [Abstract][Full Text] [Related]
16. [TGF-beta and platelet].
Kogawa K; Mogi Y; Morii K; Takimoto R; Niitsu Y
Rinsho Ketsueki; 1994 Apr; 35(4):370-5. PubMed ID: 8028182
[TBL] [Abstract][Full Text] [Related]
17. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.
Goette NP; Lev PR; Heller PG; Kornblihtt LI; Korin L; Molinas FC; Marta RF
Cytokine; 2010 Jul; 51(1):67-72. PubMed ID: 20483636
[TBL] [Abstract][Full Text] [Related]
18. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis.
Harrison JS; Corcoran KE; Joshi D; Sophacleus C; Rameshwar P
Am J Hematol; 2006 Jan; 81(1):51-8. PubMed ID: 16369977
[TBL] [Abstract][Full Text] [Related]
19. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms.
Li Y; Gao H; Dong H; Wang W; Xu Z; Wang G; Liu Y; Wang H; Ju W; Qiao J; Xu K; Fu C; Zeng L
Biochem Pharmacol; 2022 May; 199():115013. PubMed ID: 35318038
[TBL] [Abstract][Full Text] [Related]
20. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
Gilbert HS
Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
